CASH 2026 | Professor Zhigang Cai: Breakthrough Advances in Clonal Hematopoiesis, MDS, MPN, and VEXAS Syndrome

CASH 2026 | Professor Zhigang Cai: Breakthrough Advances in Clonal Hematopoiesis, MDS, MPN, and VEXAS Syndrome

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held in Tianjin. The meeting brought together leading international and national experts in hematology, focusing on frontier scientific advances and national health priorities, fostering deep academic exchange and shaping future directions of the discipline.
CASH 2026 | Professor Jian Li: Peking Union Medical College Hospital’s Experience in the Diagnosis and Treatment of AL Amyloidosis

CASH 2026 | Professor Jian Li: Peking Union Medical College Hospital’s Experience in the Diagnosis and Treatment of AL Amyloidosis

As the new year begins, leading experts gathered in Tianjin. From  January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held, bringing together top hematology specialists from China and abroad. The conference focused on cutting-edge scientific progress and national health priorities, fostering in-depth discussions on the future of hematology.
How to Develop Personalized Bladder-Preserving Strategies for MIBC? Professor Yijun Shen Shares MDT Experience and Clinical Decision Pathways

How to Develop Personalized Bladder-Preserving Strategies for MIBC? Professor Yijun Shen Shares MDT Experience and Clinical Decision Pathways

From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and real-world clinical challenges, with the goal of fostering academic innovation and supporting the development of young clinicians.
Professor Lei Fan: The Evolving Landscape and Future Directions of First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) | 2026 CSCO Hematologic Oncology Conference

Professor Lei Fan: The Evolving Landscape and Future Directions of First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) | 2026 CSCO Hematologic Oncology Conference

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the conference, Professor Lei Fan from Jiangsu Provincial People’s Hospital presented a comprehensive overview of the latest advances, current standards, and future directions in first-line treatment for chronic lymphocytic leukemia (CLL), offering valuable guidance for optimizing clinical management.
Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint

Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Guided by the overarching vision of “Greater Hematology, Greater Public Health, and Greater Health,” CSCO’s hematology committees have built a four-pillar framework centered on standardization, clinical support, collaboration, and prognostic assessment, and a three-core value system emphasizing guideline implementation, resource decentralization, and academic empowerment.
Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

The combination of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) is rapidly transforming the clinical management of urothelial carcinoma. Meanwhile, circulating tumor DNA (ctDNA) is emerging as a highly promising biomarker, offering critical support for precision medicine and bladder-preserving treatment strategies.
Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

The Infectious Diseases Society of America (IDSA) has recently released its Clinical Practice Guidelines for the Treatment and Management of Complicated Urinary Tract Infections (cUTI)—the first IDSA guideline dedicated specifically to cUTI. The updated guideline revises the definition of cUTI and proposes a four-step framework to support individualized empiric treatment decisions.
Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer

Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer

Recently, the Department of Urology at Jiangsu Provincial People’s Hospital, led by Professor Qiang Lü, published a multicenter study in EClinicalMedicine (CAS Zone 1, Impact Factor = 10.0). By integrating multicenter MRI data, the research team developed a multimodal fusion–based deep learning model designed to achieve noninvasive preoperative survival prediction in bladder cancer patients.